share_log

Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 4.8%

Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 4.8%

万达制药(纳斯达克：VNDA)股价上涨4.8%
Financial News Live ·  2022/08/30 12:41

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating)'s stock price was up 4.8% during trading on Tuesday . The stock traded as high as $10.98 and last traded at $10.95. Approximately 4,637 shares traded hands during trading, a decline of 99% from the average daily volume of 382,612 shares. The stock had previously closed at $10.45.

在周二的交易中，万达制药股份有限公司(纳斯达克代码：VNDA-GET Rating)的股价上涨了4.8%。该股盘中一度涨至10.98美元，最新报10.95美元。该股全天约有4,637股易手，较382,612股的日均成交量下降了99%。此前该股收盘价为10.45美元。

Analyst Upgrades and Downgrades

分析师升级和下调评级

Separately, StockNews.com upgraded shares of Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, June 3rd.

另外，在6月3日周五的一份研究报告中，StockNews.com将万达制药的股票评级从持有上调至买入。

Get
到达
Vanda Pharmaceuticals
万达制药
alerts:
警报：

Vanda Pharmaceuticals Trading Up 4.3 %

万达制药股价上涨4.3%

The stock has a market cap of $616.50 million, a price-to-earnings ratio of 52.25 and a beta of 0.47. The stock's 50-day moving average price is $10.80 and its 200-day moving average price is $10.89.

该股市值为6.165亿美元，市盈率为52.25倍，贝塔系数为0.47。该股的50日移动均线价格为10.80美元，200日移动均线价格为10.89美元。

Insider Transactions at Vanda Pharmaceuticals

万达制药的内幕交易

In other news, Director Stephen Ray Mitchell sold 2,700 shares of the business's stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the transaction, the director now owns 6,515 shares in the company, valued at approximately $61,762.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Stephen Ray Mitchell sold 2,700 shares of the business's stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the transaction, the director now owns 6,515 shares in the company, valued at approximately $61,762.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Joakim Wijkstrom sold 3,605 shares of the business's stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total transaction of $37,023.35. Following the completion of the transaction, the chief marketing officer now owns 96,673 shares in the company, valued at approximately $992,831.71. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,544 shares of company stock worth $87,181. Company insiders own 7.00% of the company's stock.
在其他新闻方面，董事斯蒂芬·雷·米切尔在6月13日(星期一)的一笔交易中出售了2,700股该公司的股票。这些股票的平均价格为9.48美元，总价值为25,596.00美元。交易完成后，董事现在拥有该公司6,515股股份，价值约61,762.20美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，用户可以通过美国证券交易委员会网站查看该文件。在其他新闻方面，董事斯蒂芬·雷·米切尔在6月13日(星期一)的一笔交易中出售了2,700股该公司的股票。这些股票的平均价格为9.48美元，总价值为25,596.00美元。交易完成后，董事现在拥有该公司6,515股股份，价值约61,762.20美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，用户可以通过美国证券交易委员会网站查看该文件。此外，首席营销官Joakim Wijkstrom在8月22日星期一的一次交易中出售了3605股该公司的股票。该股以10.27美元的平均价格出售，总成交金额为37,023.35美元。交易完成后，首席营销官现在拥有该公司96,673股股票，价值约992,831.71美元。此次拍卖的披露信息可在此处找到。在过去的90天里，内部人士出售了8,544股公司股票，价值87,181美元。公司内部人士持有该公司7.00%的股份。

Institutional Inflows and Outflows

机构资金流入和流出

A number of institutional investors have recently modified their holdings of the stock. Wedge Capital Management L L P NC lifted its position in shares of Vanda Pharmaceuticals by 8.8% during the 2nd quarter. Wedge Capital Management L L P NC now owns 11,206 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 902 shares during the period. Ziegler Capital Management LLC increased its stake in Vanda Pharmaceuticals by 2.6% during the 2nd quarter. Ziegler Capital Management LLC now owns 39,454 shares of the biopharmaceutical company's stock valued at $430,000 after purchasing an additional 1,016 shares in the last quarter. Texas Permanent School Fund increased its stake in Vanda Pharmaceuticals by 2.8% during the 2nd quarter. Texas Permanent School Fund now owns 40,591 shares of the biopharmaceutical company's stock valued at $442,000 after purchasing an additional 1,094 shares in the last quarter. Comerica Bank increased its stake in Vanda Pharmaceuticals by 2.5% during the 1st quarter. Comerica Bank now owns 47,706 shares of the biopharmaceutical company's stock valued at $537,000 after purchasing an additional 1,180 shares in the last quarter. Finally, Yousif Capital Management LLC increased its stake in Vanda Pharmaceuticals by 2.4% during the 1st quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company's stock valued at $574,000 after purchasing an additional 1,180 shares in the last quarter. Institutional investors and hedge funds own 99.42% of the company's stock.

一些机构投资者最近调整了对该股的持有量。Wdge Capital Management L L P NC在第二季度将其在Vanda PharmPharmticals股票的头寸提高了8.8%。韦奇资本管理公司现在拥有11,206股这家生物制药公司的股票，价值122,000美元，在此期间又购买了902股。Ziegler Capital Management LLC在第二季度增持了2.6%的万达制药股份。Ziegler Capital Management LLC现在持有这家生物制药公司39,454股股票，价值43万美元，上个季度又购买了1,016股。德州永久学校基金在第二季度增持了2.8%的万达制药股份。德克萨斯永久学校基金在上个季度又购买了1,094股后，现在拥有40,591股这家生物制药公司的股票，价值442,000美元。Comerica银行在第一季度增持了2.5%的Vanda PharmPharmticals股份。Comerica银行现在持有这家生物制药公司47,706股股票，价值537,000美元，上个季度又购买了1,180股。最后，Yousif Capital Management LLC在第一季度增持了2.4%的Vanda PharmPharmticals股份。Yousif Capital Management LLC现在拥有50,710股这家生物制药公司的股票，价值57.4万美元，上个季度又购买了1,180股。机构投资者和对冲基金持有该公司99.42%的股票。

About Vanda Pharmaceuticals

关于万达制药

(Get Rating)

(获取评级)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

万达制药公司是一家生物制药公司，专注于疗法的开发和商业化，以满足高度未得到满足的医疗需求。该公司的营销产品包括用于治疗非24小时睡眠-觉醒障碍的Hetlioz；以及用于治疗精神分裂症的Fanapt口服药片。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
  • Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
  • The Retail Sector: Winners And Losers From Q2 Earnings
  • Can Targa Continue Rallying To Meet Its Price Target?
  • Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
  • MarketBeat Podcast: The Time For Cloud Stocks May Be Now
  • 免费获取StockNews.com关于万达制药的研究报告(VNDA)
  • 减震器：颠簸时代的3只低波动率红利股票
  • 零售业：第二季度收益的赢家和输家
  • Targa能否继续反弹以实现其价格目标？
  • 在拒绝了AppLovin的报价后，Unity Software准备好重整旗鼓了吗？
  • MarketBeat播客：云股票的时代可能就是现在

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

获得《Vanda PharmPharmticals Daily》新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vanda PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发